Results 141 to 150 of about 5,137,646 (317)

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

open access: yesMolecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober   +16 more
wiley   +1 more source

Aurora Health Care Patient Service Market Leaders, 2009-11

open access: yes, 2020
Aurora Health Care, Wisconsin: Brochure with information on Aurora Health Care\u27s eleven patient service markets and their leaders.https://institutionalrepository.aah.org/ahc_books/1159/thumbnail ...
Advocate Aurora Health
core  

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Advocate Health Care Annual Report, 2004

open access: yes
Advocate Health Care, Oak Brook, IL: Annual report for Advocate Health Care titled Together . Includes marketing and financial information for 2004.https://institutionalrepository.aah.org/alldocuments/1778/thumbnail ...
Advocate Health - Midwest
core  

For more Mangomoments in health care! [PDF]

open access: yesEinstein (Sao Paulo)
Tartaglia A   +3 more
europepmc   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Advocate Health Care Annual Report, 2001

open access: yes
Advocate Health Care, Oak Brook, IL: Annual report for Advocate Health Care titled Leading . Includes data, statistics, and development plans for 9 legacy hospitals and out-patient centers.
Advocate Health - Midwest
core  

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

open access: yesMolecular Oncology, EarlyView.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski   +10 more
wiley   +1 more source

Advocate Health Care Community Benefits Journal, 2006

open access: yes
Advocate Health Care, Oak Brook, IL: Community Benefits Journal for Advocate Health Care titled, Impact . Includes data, statistics, and development plans for eight legacy hospitals and out-patient centers.
Advocate Health - Midwest
core  

Home - About - Disclaimer - Privacy